Onkologie. 2021:15(1):9-14 | DOI: 10.36290/xon.2021.002

Nutritional and anticancer therapy in cancer patients with low muscle mass

Viktor Maňásek1, Kamil Bezděk2
1 Komplexní onkologické centrum, Nemocnice Agel, Nový Jičín, a. s.
2 Nutriční ambulance a odd. ARO, Nemocnice Agel, Nový Jičín, a. s.

The loss of muscle mass is a phenomenon encountered relatively frequently in oncology. Not only the total weight, but also the composition of body mass (muscle and adipose tissue) has a major influence on the effectiveness of anticancer treatment and its toxicity. Various anticancer drugs have different effects on muscle metabolism. We summarize not only the actions of cytostatics and targeted therapies, but also modern immuno-oncological treatment. First of all, the link between body composition and anticancer activity. Basic recommendations for nutrition procedures in patients with low muscle mass are summarised.

Keywords: nutrition therapy, sarcopenia, chemotherapy, targeted therapy, imunotherapy.

Published: March 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Maňásek V, Bezděk K. Nutritional and anticancer therapy in cancer patients with low muscle mass. Onkologie. 2021;15(1):9-14. doi: 10.36290/xon.2021.002.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mošnová V, Šachlová M, Benešová V, Holečková P, Maňásek V, et al. Nutriaction - nutriční screening v onkologických ambulancích. XXXV. Brněnské onkologické dny. 2011: Poster. Číslo abstraktu: 212p.
    2. Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl. Physiol. Nutr. Metab. 2008; 33: 997-1006. Go to original source... Go to PubMed...
    3. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013; 31(12): 1539-47. doi: 10.1200/JCO.2012.45.2722. Epub 2013 Mar 25. PMID: 23530101. Go to original source... Go to PubMed...
    4. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008; 9: 629-635. Go to original source... Go to PubMed...
    5. Prado CMM, Antoun S, Sawyer MB, Baracos VE. Two faces of drug therapy in cancer: drug related lean tissue loss and its adverse consequences to survival and toxicity. Current Opinion in Clinical Nutrition and Metabolic Care 2011, 14: 250-254. Go to original source... Go to PubMed...
    6. Antoun S, Baracos VE, Birdsell L, et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010; 21: 1594-1598. Go to original source... Go to PubMed...
    7. Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin. Cancer Res. 2007; 13: 3264-3268. Go to original source... Go to PubMed...
    8. Baracos VE, Arribas L. Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann Oncol. 2018 Feb 1; 29(suppl_2): ii1-ii9. doi: 10.1093/annonc/mdx810. PMID: 29506228. Go to original source...
    9. Lee JS, Kim YS, Kim EY, Jin W. Prognostic significance of CT - determined sarcopenia in patients with advanced gastric cancer. PLoS One. 2018; 13(8): e0202700. doi: 10.1371/journal.pone.0202700. PMID: 30125312; PMCID: PMC6101416. Go to original source... Go to PubMed...
    10. Chindapasirt J. Sarcopenia in cancer patients. Asian Pac J Cancer Prev 2015; 16: 8075-8077. Go to original source... Go to PubMed...
    11. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M. European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39(4): 412-423. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13. PMID: 20392703; PMCID: PMC2886201. Go to original source... Go to PubMed...
    12. Prado CM, Purcell SA, Laviano A. Nutrition interventions to treat low muscle mass in cancer. J Cachexia Sarcopenia Muscle 2020; 11: 366-380. Go to original source... Go to PubMed...
    13. Villaseñor A, Ballard-Barbash R, Baumgartner K, Baumgartner R, Bernstein L, McTiernan A, Neuhouser ML. Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. J Cancer Surviv. 2012; 6(4): 398-406. doi: 10.1007/s11764-012-0234-x. Epub 2012 Oct 4. PMID: 23054848; PMCID: PMC3747827. Go to original source... Go to PubMed...
    14. Luciani A, Gilda A, Tagliabue L, Gilardi L, Oldani S, Codecà C, Caldiera S, Lucignani G, Foa P. The impact of chemotherapy on sarcopenia and fatigue in elderly cancer patients: a prospective pilot study. Journal of Clinical Oncology 2008; 26: 15_suppl, 9635-9635. Go to original source...
    15. Barret M, Malka D, Aparicio T, Dalban C, Locher C, Sabate JM, Louafi S, Mansourbakht T, Bonnetain F, Attar A, Taieb J. Nutritional status affects treatment tolerability and survival in metastatic colorectal cancer patients: results of an AGEO prospective multicenter study. Oncology 2011; 81(5-6): 395-402. doi: 10.1159/000335478. Epub 2012 Jan 20. PMID: 22269999. Go to original source... Go to PubMed...
    16. Lieffers, et al. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer. 2012 Sep 4; 107(6): 931-6. doi: 10.1038/bjc.2012.350. Epub 2012 Aug 7. Go to original source... Go to PubMed...
    17. Chung E, Lee HS, Cho ES, Park EJ, Baik SH, Lee KY, Kang J. Changes in Body Composition During Adjuvant FOLFOX Chemotherapy and Overall Survival in Non-Metastatic Colon Cancer. Cancers (Basel). 2019; 12(1): 60. doi: 10.3390/cancers12010060. PMID: 31878325; PMCID: PMC7016804. Go to original source... Go to PubMed...
    18. Bossola M, Pacelli F, Rosa F, Tortorelli A, Doglietto GB. Does nutrition support stimulate tumor growth in humans? Nutrition in Clinical Practice: Official Publication of the American Society for Parenteral and Enteral Nutrition 2011; 26(2): 174-180. doi: 10.1177/0884533611399771. Go to original source... Go to PubMed...
    19. Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Fearon K, Hütterer E, Isenring E, Kaasa S, Krznaric Z, Laird B, Larsson M, Laviano A, Mühlebach S, Muscaritoli M, Oldervoll L, Ravasco P, Solheim T, Strasser F, de van der Schueren M, Preiser JC. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017; 36(1): 11-48. doi: 10.1016/j.clnu.2016.07.015. Epub 2016 Aug 6. PMID: 27637832. Go to original source... Go to PubMed...
    20. Schmitz KH, Ahmed RL, Hannan PJ, Yee D. Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteins. Cancer Epidemiol Biomarkers Prev. 2005; 14(7): 1672-80. doi: 10.1158/1055-9965.EPI-04-0736. PMID: 16030100. Go to original source... Go to PubMed...
    21. Maňásek V, Bezděk K, Foltys A, Klos K, Smitka J, Smehlik D. The Impact of High Protein Nutritional Support on Clinical Outcomes and Treatment Costs of Patients with Colorectal Cancer. Klin Onkol. 2016; 29(5): 351-357. English PMID: 27739314. Go to original source... Go to PubMed...
    22. Rauh S, Antonuzzo A, Bossi P, Eckert R, Fallon M, Fröbe A, Gonella S, Giusti R, Lakatos G, Santini D, Villarini A. Nutrition in patients with cancer: a new area for medical oncologists? A practising oncologist's interdisciplinary position paper. ESMO Open. 2018; 3(4): e000345. doi: 10.1136/esmoopen-2018-000345. PMID: 29765772; PMCID: PMC5950635. Go to original source... Go to PubMed...
    23. Davis MP, Panikkar R. Sarcopenia associated with chemotherapy and targeted agents for cancer therapy. Ann Palliat Med. 2019; 8(1): 86-101. doi: 10.21037/apm.2018.08.02. Epub 2018 Sep 7. PMID: 30525762. Go to original source... Go to PubMed...
    24. Quan-Jun Y, Yan H, Yong-Long H, Li-Li W, Jie L, Jin-Lu H, Jin L, Peng-Guo C, Run G, Cheng G. Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation. Mol Cancer Ther. 2017; 16(2): 334-343. doi: 10.1158/1535-7163.MCT-16-0324. Epub 2016 Sep 6. PMID: 27599525. Go to original source... Go to PubMed...
    25. Prado CM, Bekaii-Saab T, Doyle LA, Shrestha S, Ghosh S, Baracos VE, Sawyer MB. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer. 2012; 106(10): 1583-6. doi: 10.1038/bjc.2012.144. Epub 2012 Apr 17. PMID: 22510747; PMCID: PMC3349178. Go to original source... Go to PubMed...
    26. Ito T, Ogawa R, Uezumi A, Ohtani T, Watanabe Y, Tsujikawa K, Miyagoe-Suzuki Y, Takeda S, Yamamoto H, Fukada S. Imatinib attenuates severe mouse dystrophy and inhibits proliferation and fibrosis-marker expression in muscle mesenchymal progenitors. Neuromuscul Disord. 2013; 23(4): 349-56. doi: 10.1016/j.nmd.2012.10.025. Epub 2013 Jan 10. PMID: 23313020. Go to original source... Go to PubMed...
    27. Moryoussef F, Dhooge M, Volet J, Barbe C, Brezault C, Hoeffel C, Coriat R, Bouché O. Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib. J Cachexia Sarcopenia Muscle. 2015; 6(4): 343-50. doi: 10.1002/jcsm.12047. Epub 2015 Jun 4. PMID: 26673372; PMCID: PMC4670743. Go to original source... Go to PubMed...
    28. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010; 28(6): 1054-60. doi: 10.1200/JCO.2009.24.9730. Epub 2010 Jan 19. PMID: 20085939. Go to original source... Go to PubMed...
    29. Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy. Oncol Lett. 2017; 14(2): 1637-1647. doi: 10.3892/ol.2017.6287. Epub 2017 May 31. PMID: 28789390; PMCID: PMC5529937. Go to original source... Go to PubMed...
    30. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010; 21(8): 1594-1598. doi: 10.1093/annonc/mdp605. Epub 2010 Jan 20. PMID: 20089558. Go to original source... Go to PubMed...
    31. Antonelli G, Gigante E, Iavarone M, Begini P, Sangiovanni A, Iannicelli E, Biondetti P, Pellicelli AM, Miglioresi L, Marchetti P, Lampertico P, Marignani M. Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. United European Gastroenterol J. 2018; 6(7): 1039-1048. doi: 10.1177/2050640618781188. Epub 2018 May 31. PMID: 30228892; PMCID: PMC6137588. Go to original source... Go to PubMed...
    32. Huillard O, Mir O, Peyromaure M, Tlemsani C, Giroux J, Boudou-Rouquette P, Ropert S, Delongchamps NB, Zerbib M, Goldwasser F. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 2013; 108(5): 1034-41. doi: 10.1038/bjc.2013.58. Epub 2013 Mar 5. PMID: 23462722; PMCID: PMC3619075. Go to original source... Go to PubMed...
    33. Gyawali B, Shimokata T, Honda K, Kondoh C, Hayashi N, Yoshino Y, Sassa N, Nakano Y, Gotoh M, Ando Y. Muscle wasting associated with the long-term use of mTOR inhibitors. Mol Clin Oncol. 2016; 5(5): 641-646. doi: 10.3892/mco.2016.1015. Epub 2016 Sep 13. PMID: 27900103; PMCID: PMC5103886. Go to original source... Go to PubMed...
    34. Auclin E, Bourillon C, De Maio E, By MA, Seddik S, Fournier L, Auvray M, Dautruche A, Vano YA, Thibault C, Joly F, Brunereau L, Gomez-Roca C, Chevreau C, Elaidi R, Oudard S. Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer 2017; 15(3): 350-355. doi: 10.1016/j.clgc.2017.01.022. Epub 2017 Feb 1. PMID: 28216276. Go to original source... Go to PubMed...
    35. May PE, Barber A, D'Olimpio JT, Hourihane A, Abumrad NN. Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am J Surg. 2002; 183(4): 471-9. doi: 10.1016/s0002-9610(02)00823-1. PMID: 11975938. Go to original source... Go to PubMed...
    36. Azman M, et al. Enteral glutamine supplementation in surgical patients with head and neck malignancy: A randomized controlled trial. Head Neck. 2015 Dec; 37(12): 1799-1807. doi: 10.1002/hed.23839. Epub 2015 Jun 20. PMID: 24992652. Go to original source... Go to PubMed...
    37. Pappalardo G, Almeida A, Ravasco P. Eicosapentaenoic acid in cancer improves body composition and modulates metabolism. Nutrition. 2015; 31(4): 549-55. doi: 10.1016/j.nut.2014.12.002. Epub 2014 Dec 12. PMID: 25770317. Go to original source... Go to PubMed...
    38. Ewaschuk JB, Almasud A, Mazurak VC. Role of n-3 fatty acids in muscle loss and myosteatosis. Appl Physiol Nutr Metab. 2014; 39(6): 654-62. doi: 10.1139/apnm-2013-0423. Epub 2014 Jan 24. PMID: 24869970. Go to original source... Go to PubMed...
    39. Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC. Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer 2011; 117(16): 3774-80. doi: 10.1002/cncr.25933. Epub 2011 Feb 15. PMID: 21328326. Go to original source... Go to PubMed...
    40. Mochamat, Cuhls H, Marinova M, Kaasa S, Stieber C, Conrad R, Radbruch L, Mücke M. A systematic review on the role of vitamins, minerals, proteins, and other supplements for the treatment of cachexia in cancer: a European Palliative Care Research Centre cachexia project. J Cachexia Sarcopenia Muscle 2017; 8(1): 25-39. doi: 10.1002/jcsm.12127. Epub 2016 Jul 20. PMID: 27897391; PMCID: PMC5326814. Go to original source... Go to PubMed...
    41. Visser M, Deeg DJ, Lips P; Longitudinal Aging Study Amsterdam. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab. 2003; 88(12): 5766-72. doi: 10.1210/jc.2003-030604. PMID: 14671166. Go to original source... Go to PubMed...
    42. Fuller JC Jr, Baier S, Flakoll P, Nissen SL, Abumrad NN, Rathmacher JA. Vitamin D status affects strength gains in older adults supplemented with a combination of β-hydroxy-β-methylbutyrate, arginine, and lysine: a cohort study. JPEN J Parenter Enteral Nutr. 2011; 35(6): 757-62. doi: 10.1177/0148607111413903. Epub 2011 Aug 1. PMID: 21807930. Go to original source... Go to PubMed...
    43. Sawka MN. Physiological consequences of hypohydration: exercise performance and thermoregulation. Med Sci Sports Exerc. 1992; 24(6): 657-70. PMID: 1602938. Go to original source...
    44. Hargreaves M, Febbraio M. Limits to exercise performance in the heat. Int J Sports Med. 1998; 19 Suppl 2: S115-6. doi: 10.1055/s-2007-971973. PMID: 9694414. Go to original source... Go to PubMed...
    45. Volpe SL. Serving on the Institute of Medicine's Dietary Reference Intake Panel for Electrolytes and Water. J Am Diet Assoc. 2004; 104(12): 1885-7. doi: 10.1016/j.jada.2004.10.013. PMID: 15565086. Go to original source... Go to PubMed...
    46. De Spiegeleer A, Petrovic M, Boeckxstaens P, Van Den Noortgate N. Treating sarcopenia in clinical practice: where are we now? Acta Clin Belg. 2016; 71(4): 197-205. doi: 10.1080/17843286.2016.1168064. Epub 2016 Apr 26. PMID: 27112427. Go to original source... Go to PubMed...
    47. Phillips SM. Nutritional supplements in support of resistance exercise to counter age-related sarcopenia. Adv Nutr. 2015; 6(4): 452-60. doi: 10.3945/an.115.008367. PMID: 26178029; PMCID: PMC4496741. Go to original source... Go to PubMed...
    48. Rodacki CL, Rodacki AL, Pereira G, Naliwaiko K, Coelho I, Pequito D, Fernandes LC. Fish-oil supplementation enhances the effects of strength training in elderly women. Am J Clin Nutr. 2012; 95(2): 428-36. doi: 10.3945/ajcn.111.021915. Epub 2012 Jan 4. PMID: 22218156. Go to original source... Go to PubMed...
    49. Cortellini A, Bersanelli M, Buti S, et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer 2019; 7(1): 57. doi: 10.1186/s40425-019-0527-y. PMID: 30813970; PMCID: PMC6391761. Go to original source... Go to PubMed...
    50. McQuade JL, Daniel CR, Hess KR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018; 19(3): 310-322. doi: 10.1016/S1470-2045(18)30078-0. Epub 2018 Feb 12. PMID: 29449192; PMCID: PMC5840029. Go to original source... Go to PubMed...
    51. Heidelberger V, Goldwasser F, Kramkimel N, et al. Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Invest New Drugs. 2017; 35(4): 436-441. doi: 10.1007/s10637-017-0464-x. Epub 2017 Apr 10. Erratum in: Invest New Drugs. 2017 Jun 9; PMID: 28396974. Go to original source... Go to PubMed...
    52. Richtig G, Hoeller C, Wolf M, et al. Body mass index may predict the response to ipilimumab in metastatic melanoma: an observational multi-centre study. PLoS One. 2018; 13(10): e0204729. doi: 10.1371/journal.pone.0204729. PMID: 30273398; PMCID: PMC6166940. Go to original source... Go to PubMed...
    53. Wang Z, Aguilar EG, Luna JI, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019; 25(1): 141-151. doi: 10.1038/s41591-018-0221-5. Epub 2018 Nov 12. PMID: 30420753; PMCID: PMC6324991. Go to original source... Go to PubMed...
    54. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011; 11(2): 85-97. doi: 10.1038/nri2921. Epub 2011 Jan 21. PMID: 21252989; PMCID: PMC3518031. Go to original source... Go to PubMed...
    55. Han SJ, Glatman Zaretsky A, Andrade-Oliveira V, et al. White Adipose Tissue Is a Reservoir for Memory T Cells and Promotes Protective Memory Responses to Infection. Immunity 2017; 47(6): 1154-1168.e6. doi: 10.1016/j.immuni.2017.11.009. Epub 2017 Dec 5. PMID: 29221731; PMCID: PMC5773068. Go to original source... Go to PubMed...
    56. Muscaritoli M, Molfino A, Gioia G, Laviano A, Rossi Fanelli F. The "parallel pathway": a novel nutritional and metabolic approach to cancer patients. Intern Emerg Med. 2011; 6(2): 105-12. doi: 10.1007/s11739-010-0426 Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.